Holly Rolley v. HHS - Tdap, Guillain-Barre Syndrome (2023)

Holly Rolley filed a petition for compensation under the National Vaccine Injury Compensation Program on May 23, 2022. She alleged that she suffered Guillain-Barre Syndrome (GBS) as a result of her Tetanus-diphtheria-acellular pertussis (Tdap) vaccination on July 3, 2019.

Ms. Rolley further alleged that she experienced residual effects for more than six months, that there had been no prior award or settlement of a civil action for damages related to her condition, and that her vaccine was administered in the United States.

The respondent denied that the Tdap vaccine caused Ms. Rolley's alleged injuries or disabilities, or that it significantly aggravated any underlying conditions.

Despite the respondent's denial, the parties filed a joint stipulation on August 30, 2023, agreeing that compensation should be awarded. Special Master Daniel T.

Horner reviewed the stipulation, found it reasonable, and adopted it as the decision of the Court. Pursuant to the stipulation, Holly Rolley was awarded a lump sum of $66,100.80, payable to her.

This amount represents compensation for all items of damages available under the Vaccine Act. The case was resolved via joint stipulation, and judgment was to be entered accordingly.

The public decision does not describe the specific onset of symptoms, diagnostic tests, treatments, or expert witnesses. Petitioner was represented by Leah VaSahnja Durant of the Law Offices of Leah V.

Durant, PLLC, and respondent was represented by Parisa Tabassian of the U.S. Department of Justice.